Joseph Tucker was appointed Director of Lakewood-Amedex Biotherapeutics Inc., effective April 24, 2026. As of November 6, 2026, Lakewood-Amedex Biotherapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 28, 2026, naming 1 appointment (Form 8-K, April 28, 2026).
Who owns Lakewood-Amedex Biotherapeutics Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Lakewood-Amedex Biotherapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lakewood-Amedex Biotherapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-28. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Lakewood-Amedex Biotherapeutics Inc. files it.
Also on the record for Lakewood-Amedex Biotherapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by WFI Equity, LLC | 8.8% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by LINDESFARNE LLC | 9.88% of the class | 5%+ stakes | Source |
| June 23, 2026 | Stake report, Schedule 13G, by HPW Investments Holding Ltd. | 24.04% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lakewood-Amedex Biotherapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Lakewood-Amedex Biotherapeutics Inc. and the records around it.
Lakewood-Amedex Biotherapeutics Inc. elsewhere on the record
Watch Lakewood-Amedex Biotherapeutics Inc.
Get an email when Lakewood-Amedex Biotherapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lakewood-Amedex Biotherapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lakewood-Amedex Biotherapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lakewood-Amedex Biotherapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-28 | In | Director | 2026-04-24 | 8-K, 2026-04-28 |
Who leads Lakewood-Amedex Biotherapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Joseph Tucker, appointed, effective 2026-04-24 (filed 2026-04-28).
New leaders reset buying decisions — get the Full Report on Lakewood-Amedex Biotherapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Lakewood-Amedex Biotherapeutics Inc., with the record behind each one.
Find candidates like Director at Lakewood-Amedex Biotherapeutics Inc.Every change, in the filing's words
Appointed: Joseph Tucker, Director, effective 2026-04-24
On April 24, 2026, the Board of Directors (the "Board") of Lakewood-Amedex Biotherapeutics Inc. (the "Company") appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026.
- He will serve until the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.
- Dr. Tucker, age 57, has served as Chief Executive Officer and Director of Enveric Biosciences Inc. (NASDAQ: ENVB) since September 2021, following Enveric's acquisition of MagicMed Industries, where he served as Chief Executive Officer, President, and Director beginning in 2020.
- From 2016 to 2022, Dr. Tucker served as Chief Executive Officer, President, and Director of VirTech Bio, Inc., an early-stage biotechnology company.
- From 2014 to 2020, Dr. Tucker served as Executive Chairman, Chief Executive Officer, President, and Director of Willow Biosciences Inc. (TSX: WLLW) and its predecessor company, Epimeron Inc. From 2004 to 2007, Dr. Tucker served as Chief Executive Officer, President, and Director of Stem Cell Therapeutics Corp. (TSX: SSS), which he took public via initial public offering and which ultimately merged into Trillium Therapeutics Inc. (NASDAQ: TRIL), later acquired by Pfizer Inc. (NYSE: PFE).
- Dr. Tucker previously served as Vice President of Resverlogix (TSX: RVX) from 2003 to 2004 and Vice President of Neurostasis, Inc. from 2001 to 2003.
- Earlier in his career, Dr. Tucker served as a lead health care analyst at Lightyear Capital Inc. and Acumen Capital Partners Inc. from 2000 to 2001.
Tools for this story
Each opens in a new tab, filled in for Lakewood-Amedex Biotherapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.